Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies

Published by: BioSeeker Group AB

Published: May. 29, 2006 - 322 Pages

Table of Contents

1 Executive Summary

2 Methodology

3 Table of Contents

3.1 List of Boxes

3.2 List of Figures

3.3 List of Tables

4 Lymphoma Therapeutics

4.1 Introduction

4.1.1 Disease Definition

4.1.2 Etiology & Pathophysiology

4.1.3 Epidemiology

4.2 Current Treatment Strategies

4.2.1 Hodgkin's Disease

4.2.2 Non-Hodgkin's Lymphoma

4.2.3 Prognosis

4.3 Progress in Current Treatment Strategies

4.3.1 HODGKIN

4.3.2 NON-HODGKIN

4.4 Key Therapeutic Strategies

4.4.1 Antibodies & Immunostimulation

4.4.2 Small molecules: Apoptosis inducers & Kinase inhibitors

4.5 Current Drug Development: The Late Stage Pipeline

4.5.1 Progress Analysis: aldesleukin

4.5.2 Progress Analysis: Arsenic trioxide

4.5.3 Progress Analysis: BiovaxID

4.5.4 Progress Analysis: bortezomib

4.5.5 Progress Analysis: LymphoCide

4.5.6 Progress Analysis: FavId

4.5.7 Progress Analysis: MyVax

4.5.8 Progress Analysis: Nelarabine

4.5.9 Progress Analysis: Genasense

4.5.10 Progress Analysis: Marqibo

4.5.11 Progress Analysis: Pixantrone

4.5.12 Progress Analysis: CCI-779

4.5.13 Progress Analysis: HuMax-CD4

4.5.14 Progress Analysis: Bortezomib

4.6 Current Drug Development: The Early Stage Pipeline

4.6.1 Progress analysis: bevacizumab

4.6.2 Progress Analysis: CMC-544

4.6.3 Progress Analysis: galiximab

4.6.4 Progress Analysis: LY317615

4.6.5 Progress Analysis: SGN-40

4.6.6 Progress Analysis: Hu1D10

4.6.7 Progress Analysis: SGN-30

5 Therapeutic Antibodies

5.1 Key Developmental Strategies

5.2 Treating Colorectal Cancer

5.2.1 Avastin

5.2.2 Erbitux

5.3 Treating Lymphomas

5.3.1 Rituxan

5.3.2 Bexxar

5.3.3 Zevalin

5.4 Treating Leukemias

5.4.1 ALL

5.4.2 CLL

5.4.3 AML

5.4.4 CML

5.4.5 Campath

5.4.6 Mylotarg

5.5 Treating Lung cancer

5.5.1 Cotara

5.6 Antibody Deals on the Rise

5.6.1 Antibody Deals in Phase III

5.6.2 Antibody Deals in Phase II

5.7 New Approaches in Antibody Delivery and Design - The Next Generation

5.7.1 How to Make Them Smaller and Different?

5.7.2 Biomaterials in Sustained Delivery Applications

5.7.3 Gene delivery - the Future?

5.8 Current Analysis of Antibodies in Clinical Development

5.8.1 Prostate Cancer Therapeutics

5.8.2 Breast Cancer Therapeutics

5.8.3 Colorectal Cancer Therapeutics

5.8.4 Melanoma Therapeutics

5.8.5 Hematological Cancers Therapeutics

5.9 Antibodies in Phase III Clinical Development

5.9.1 Progress Analysis: IGN 101

5.9.2 Progress Analysis: MDX 010

5.9.3 Progress Analysis: ONYVAX 105

5.9.4 Progress Analysis: Ovarex

5.9.5 Progress Analysis: Panitumumab

5.9.6 Progress Analysis: RENCAREX

5.9.7 Progress Analysis: Nimotuzumab

5.9.8 Progress Analysis: TransMID

5.9.9 Progress Analysis: Lintuzumab

5.9.10 Progress Analysis: Zanolimumab

5.10 Antibodies in Phase II Clinical Development

5.10.1 Progress Analysis: ABT-510

5.10.2 Progress Analysis: BB 10901

5.10.3 Progress Analysis: CP 675206

5.10.4 Progress Analysis: CNTO-328

5.10.5 Progress Analysis: Ecromeximab

5.10.6 Progress Analysis: EMD 273063

5.10.7 Progress Analysis: WX-G250RIT

5.10.8 Progress Analysis: HGS-ETR1

5.10.9 Progress Analysis: HuMax-CD20

5.10.10 Progress Analysis: HuMax-EGFr

5.10.11 Progress Analysis: Galiximab

5.10.12 Progress Analysis: PROXINIUM

5.10.13 Progress Analysis: RAV12

5.10.14 Progress Analysis: SGN-15

5.10.15 Progress Analysis: SGN-30

5.10.16 Progression Analysis: VEGF-Trap

5.10.17 Progress Analysis: MEDI 522

5.10.18 Progress Analysis: Volociximab

5.11 Cancer Therapeutic Antibodies in Clinical Development

6 Protein Kinase Inhibitors

6.1 Rationale for Development of Kinase Inhibitors in Oncology

6.2 Protein Kinase Targets - A Growing Family

6.3 Challenges in Protein Kinase Drug Discovery

6.3.1 Enabling Structure-Based Drug Design is the Key

6.3.2 Specific Kinase Inhibitors without Kinase Profiling?

6.4 Drugs according to Target

6.4.1 Cyclin-dependent Kinase Target Inhibitors

6.4.2 Aurora Kinase Target Inhibitors

6.4.3 Cell Cycle Checkpoint Target Controls Inhibitors

6.4.4 Tyrosine Kinase Receptor Inhibitors

6.4.5 Other Serine/Threonine Kinase Target Inhibitors

6.5 Dual or Multiple Kinase Inhibitor Analysis

6.5.1 Presentation of Drugs Targeting A to F Kinases

6.5.2 Presentation of Drugs Targeting G to T Kinases

6.6 Targets According to Indication

6.6.1 Breast Cancer

6.6.2 Prostate Cancer: What Cannot be Found in the ‘Groins’?

6.6.3 Lung Cancer: A Need for Improved Survival Rates

6.6.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are Others

6.6.5 Leukemia: Show Me the Power of PKI

6.6.6 Melanoma

6.6.7 Lymphoma: We Are In

6.7 Growing Competition in the Field

6.8 Big Pharma Outlook: The Race is On

6.8.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors

6.8.2 AstraZeneca - Wheeling and Dealing

6.8.3 Pfizer’s Long Look at OSI Pharmaceuticals

6.8.4 GlaxoSmithKline Gains Momentum

6.9 Strategic Deals Creating Competitive Edge

6.9.1 Mergers

6.9.2 Astex - the PKI Switchboard

6.9.3 Big Pharma’s Darling

6.10 Current Protein Kinase Inhibitors in Therapy

6.10.1 Mechanism, Target and Developmental History

6.10.2 Approvals: Indications & Markets

6.11 Protein Kinase Inhibitors in Drug Development - A Progress Analysis

6.11.1 Progress Analysis - Breast Cancer

6.11.2 Progress Analysis - Prostate Cancer

6.11.3 Progress Analysis - Lung Cancer

6.11.4 Progress Analysis - Colorectal Cancer

6.11.5 Progress Analysis - Leukemia

6.11.6 Progress Analysis - Melanoma

6.11.7 Progress Analysis - Lymphoma

7 Appendix I: Selected Company R&D Summarizes in Lymphoma

7.1.1 Accentia BioPharmaceuticals

7.1.2 Biogen Idec

7.1.3 Cell Therapeutics

7.1.4 Chiron Corporation

7.1.5 Cephalon

7.1.6 Eli Lilly

7.1.7 Favrille

7.1.8 Genentech

7.1.9 Genitope Corporation

7.1.10 Genmab

7.1.11 Genta

7.1.12 GlaxoSmithKline

7.1.13 Immunomedics

7.1.14 Inex Pharmaceuticals

7.1.15 Millennium Pharmaceuticals

7.1.16 Protein Design Labs

7.1.17 Roche

7.1.18 Sanofi-Aventis

7.1.19 Seattle Genetics

7.1.20 Wyeth

Company index

Drug index

3.1 List of Boxes

Box 1 Possible Complications of Treatment

Box 2 Updated REAL/WHO Classification for B-Cell Neoplasms

Box 3 Subclassification of stage

Box 4 Updated REAL/WHO Classification for B-Cell Neoplasms

Box 5 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms

Box 6 Staging subclassification system

Box 7 Study details

Box 8: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology

Box 9: Marrion’s Drug Delivery Technology

Box 10: Quick Facts - IGN 101

Box 11: Quick Facts - MDX 010

Box 12: Quick Facts - ONYVAX 105

Box 13: Quick Facts - Ovarex

Box 14: Quick Facts - Panitumumab

Box 15: Quick Facts - RENCARNEX

Box 16: Quick Facts - Nimotuzumab

Box 17: Quick Facts - RENCARNEX

Box 18: Quick Facts - Lintuzumab

Box 19: Quick Facts - Zanolimumab

Box 20: Quick Facts - ABT-510

Box 21: Quick Facts - BB 10901

Box 22: Quick Facts - CP-675206

Box 23: Quick Facts - CNTO-328

Box 24: Quick Facts - Ecromeximab

Box 25: Quick Facts - EMD-273063

Box 26: Quick Facts - WX-G250RIT

Box 27: Quick Facts - HGS-ETR1

Box 28: Quick Facts - HuMax-CD20

Box 29: Quick Facts - HuMax-EGFr

Box 30: Quick Facts - Galiximab

Box 31: Quick Facts - PROXINIUM

Box 32: Quick Facts - RAV12

Box 33: Quick Facts -SGN-15

Box 34: Quick Facts -SGN-30

Box 35: Quick Facts - VEGF-Trap

Box 36: Quick Facts - MEDI 522

Box 37: Quick Facts - Volociximab

Box 38: The Power of Ambit’s Kinase Profiling

Box 39: Summary Terms of the Exelixis Transaction

3.2 List of Figures

Figure 1 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.

Figure 2 Top 10 PKI Drug Developing Companies

Figure 3 Clinical Trial Distribution in Breast Cancer for PKI Drugs

Figure 4 Clinical Trial Distribution in Prostate Cancer for PKI Drugs

Figure 5 Clinical Trial Distribution in Lung Cancer for PKI Drugs

Figure 6 Clinical Trial Distribution in Colorectal Cancer for PKI Drugs

Figure 7 Clinical Trial Distribution in Leukemia for PKI Drugs

Figure 8 Clinical Trial Distribution in Melanoma for PKI Drugs

Figure 9 Clinical Trial Distribution in Lymphoma for PKI Drugs

3.3 List of Tables

Table 1 Drugs used in the treatment of lymphoma

Table 2 Summary of Strategies Enhancing Antibody Function

Table 3 Cancer immunotherapy strategies

Table 4 Protein Kinase Targets in Clinical Trials for Lymphoma

Table 5 Recent published studies Aldesleukin

Table 6 Recent published studies Arsenic trioxide

Table 7 Recent published studies BiovaxID

Table 8 Recent Published Studies Bortezomib

Table 9 Recent published studies epratuzumab

Table 10 Recent published studies FavId

Table 11 Recent published studies MyVax

Table 12 Recent published studies Nelarabine

Table 13 Recent published studies Genasense

Table 14 Recent published studies Pixantrone

Table 15 Recent published studies temsirolimus

Table 16 Recent published studies Zanolimumab

Table 17 Recent published studies Flavopiridol

Table 18 Recent published studies bevacizumab

Table 19 Recent published studies CMC-544

Table 20 Recent published studies galiximab

Table 21 Recent published studies LY317615

Table 22 Recent published studies SGN-40

Table 23 Recent published studies Apolizumab

Table 24 Recent published studies SGN-30

Table 25: Summary of Strategies Enhancing Antibody Function

Table 26: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies

Table 27: Drug Delivery Companies with Cancer Focus

Table 28: FDA Approved Polymer-based Drug Delivery Systems for Cancer

Table 29: Antibody Therapeutics in Prostate Cancer

Table 30: Antibody Therapeutics in Breast Cancer

Table 31: Antibody Therapeutics in Colorectal Cancer

Table 32: Antibody Therapeutics in Melanoma

Table 33: Antibody Therapeutics in Hematological Cancer

Table 34: MDX-010’s Collaborative History and Landscape

Table 35: Overview of Targets in Commercial Development

Table 36: Cyclin-dependent Kinase Targets in Development

Table 37: Aurora Kinase Targets in Development

Table 38: Cell Cycle Checkpoint Targets in Development

Table 39: Epidermal Growth Factor Receptor Targets in Development

Table 40: FMS-like tyrosine kinases and their Synonyms

Table 41: Fms-related Tyrosine Kinase Targets in Development

Table 42: Platelet-derived Growth Factor Receptor Targets in Development

Table 43: Kinase Insert Domain Targets in Development

Table 44: Drugs in Development Targeting the PI3K/Akt/mTOR pathway

Table 45: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway

Table 46: Serine/Threonine Kinase Inhibitors in Development

Table 47: Protein Kinase Targets in Clinical Trials for Breast Cancer

Table 48: Protein Kinase Targets in Clinical Trials for Prostate Cancer

Table 49: Protein Kinase Targets in Clinical Trials for Lung Cancer

Table 50: Protein Kinase Targets in Clinical Trials for Colorectal Cancer

Table 51: Protein Kinase Targets in Clinical Trials for Leukemia

Table 52: Protein Kinase Targets in Clinical Trials for Melanoma

Table 53: Protein Kinase Targets in Clinical Trials for Lymphoma

Table 54: Drugs in Therapy - Mechanism & Targets

Table 55: Current and Developmental History of PKI Drugs in Therapy

Table 56: Approvals: Indications & Markets

Table 57: Top 10 Drugs in Terms of Number of Clinical Trials

Table 58: List of Cancer Indications Targeted by Protein Kinase Inhibitors

Table 59: PKI Drugs in Development for Breast Cancer

Table 60: PKI Drugs in Development for Prostate Cancer

Table 61: PKI Drugs in Development for Lung Cancer

Table 62: PKI Drugs in Development for Colorectal Cancer

Table 63: PKI Drugs in Development for Leukemia

Table 64: PKI Drugs in Development for Melanoma

Table 65: PKI Drugs in Development for Lymphoma

Table 66 Accentia BioPharmaceuticals anticancer pipeline

Table 67 Biogen anticancer pipeline

Table 68 Cell Therapeutics anticancer pipeline

Table 69 Chiron Corporation anticancer pipeline

Table 70 Cephalon anticancer pipeline

Table 71 Eli Lilly anticancer pipeline

Table 72 Favrille anticancer pipeline

Table 73 Genentech anticancer pipeline

Table 74Genitope anticancer pipeline

Table 75 Genmab anticancer pipeline

Table 76 Genta anticancer pipeline

Table 77 GlaxoSmithKline anticancer pipeline

Table 78 Immunomedics anticancer pipeline

Table 79 Inex Pharmaceuticals anticancer pipeline

Table 80 Millennium Pharmaceuticals anticancer pipeline

Table 81 Protein Design Labs anticancer pipeline

Table 82 Roche anticancer pipeline

Table 83 Sanofi-Aventis anticancer pipeline

Table 84 Seattle Genetics anticancer pipeline

Table 85 Wyeth anticancer pipeline

Abstract

• Status and impact of several novel drugs in development: The lymphoma indication in specific and protein kinase inhibitors and antibodies in oncology in general
• Discussion of the challenges in current lymphoma treatment strategies.
• Thorough examination of the top cancer therapeutic strategies on the market
• Description of the race towards the next generation of therapeutics
• Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
• Competitive landscape assessment
• Thorough review of the largest cancer indications.
• Drugs according to targets
• Targets according to indication

• Gain insight into the current challenges and commercial opportunities in lymphoma treatment in specific and protein kinase inhibitors and antibodies in oncology in general.
• One source to the top cancer therapeutic on the market
• Key insights into the second wave in the lucrative field of antibody therapeutics and the promising development of protein kinase inhibitors
• Competitive landscape assessment, including deals, technologies and drug development.
• Assess opportunities and risks for the continued development of innovative developmental treatments
• Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.